Comparative Pharmacology
Head-to-head clinical analysis: NYSTATIN AND TRIAMCINOLONE ACETONIDE versus SYNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYSTATIN AND TRIAMCINOLONE ACETONIDE versus SYNACORT.
NYSTATIN AND TRIAMCINOLONE ACETONIDE vs SYNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, immune response, and vasodilation.
Synthetic corticosteroid with potent glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
Apply thin layer to affected area twice daily for 2-4 weeks. Topical only.
100 mg intravenously every 8 hours for 24 hours, then 50 mg intravenously every 8 hours for 48 hours, followed by 25 mg intravenously every 8 hours for 72 hours.
None Documented
None Documented
Nystatin: not systemically absorbed; terminal half-life not applicable. Triamcinolone acetonide: after intramuscular injection, terminal half-life is approximately 2-5 hours; after topical application, minimal systemic absorption precludes meaningful half-life determination.
Terminal elimination half-life is 2.5–3.5 hours; clinically, this short half-life requires multiple daily dosing for sustained effects.
Nystatin: primarily excreted unchanged in feces via bile (>90%); negligible renal excretion (<1%). Triamcinolone acetonide: primarily hepatically metabolized; conjugated metabolites excreted renally (70%) and via bile (20% fecal). Systemic absorption of triamcinolone acetonide after topical application is minimal (<1%).
Primarily renal (80% as metabolites, 20% unchanged); minor biliary/fecal (<5%).
Category D/X
Category C
Corticosteroid
Corticosteroid